RxDoctor Payments DataLook up a doctor →

Harmeet Singh, MD

Neurology · Leesburg, VANPI 1245271402

Payments from drug & device makers

$118,699in general payments, 2019–2025

Across 751 payments — averaging $158.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$65K
  • Ardelyx, Inc.$32K
  • Teva Pharmaceuticals USA, Inc.$8K
  • Pfizer$2K
  • Livanova USA, Inc.$1K
  • Lundbeck LLC$1K
  • plus $9K from 43 others

What the payments were for

  • Consulting fees$1,6602%
  • Speaking & faculty fees$66,11176%
  • Travel & lodging$1,5522%
  • Food & beverage$17,54020%
  • Education$1370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$118,699 in reported general payments places this provider in the 90th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$108,929
Medicare patients
295
Services billed
1,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a16$133,069
CopaxoneGlatiramer Acetate21$120,505
Kesimpta PenOfatumumab11$96,787
UbrelvyUbrogepant32$57,032
BotoxOnabotulinumtoxina17$37,912
Aimovig AutoinjectorErenumab-Aooe23$20,474
Nurtec OdtRimegepant Sulfate14$20,417
AptiomEslicarbazepine Acetate14$16,668
NeuproRotigotine12$14,912
Ajovy AutoinjectorFremanezumab-Vfrm16$13,601
NuedextaDextromethorphan Hbr/Quinidine13$11,119
Memantine Hcl ErMemantine Hcl61$7,145
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone19$4,761
Donepezil Hcl323$4,615
Dimethyl Fumarate16$3,828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$778$133,06916 claims
Teva Pharmaceuticals USA, Inc.Copaxone$8,414$120,50521 claims
AbbVieUbrelvy, Botox$65,072$94,94449 claims
PfizerNurtec Odt, Dilantin, Dilantin$1,994$24,49550 claims
UCB, Inc.Neupro$849$14,91212 claims
Avanir Pharmaceuticals, Inc.Nuedexta$222$11,11913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 neurology providers in Virginia.

Other neurology in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →